SynAct Pharma AB (STO:SYNACT)
Sweden · Delayed Price · Currency is SEK | Market Cap | 952.03M -2.2% |
| Revenue (ttm) | n/a |
| Net Income | -110.83M |
| EPS | -2.17 |
| Shares Out | 56.00M |
| PE Ratio | n/a |
| Forward PE | 16.67 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 13,847 |
| Average Volume | 160,316 |
| Open | 17.58 |
| Previous Close | 17.58 |
| Day's Range | 16.58 - 18.34 |
| 52-Week Range | 13.40 - 25.30 |
| Beta | 0.88 |
| RSI | 47.32 |
| Earnings Date | Apr 15, 2026 |
About SynAct Pharma AB
SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis, idiopathic membranous nephropathy, and virus-induced respiratory insufficiency. It is also developing TXP-11, an advanced peptide agonist that is in preclinical trials for the prevention of organ failure in surgery; and various drug programs to treat auto-immune and inflammatory diseases.... [Read more]
Financial Performance
Financial StatementsNews
SynAct Pharma AB Transcript: CMD 2026
Key clinical data from three programs are expected in the next two quarters, driving a shift to active business development. The lead RA program targets early, high-activity patients with a novel, non-immunosuppressive therapy, while host-directed therapies for respiratory infections address major unmet needs. Strong financials and a dual-track strategy support broad partnering opportunities.
SynAct Pharma AB Transcript: Life Science Summit 2025
Resomelagon is advancing in phase IIB trials for rheumatoid arthritis and host-directed viral infection therapies, with major data readouts and a dengue study expected next year. The approach targets immune modulation, aiming to improve outcomes and reduce side effects.
SynAct Pharma AB Transcript: CMD 2025
Lead RA study is on track for year-end data, with new PMR and dengue programs broadening the pipeline. Recent capital raises and a credit facility secure funding through 2026, supporting clinical and business development efforts targeting licensing or acquisition deals.
SynAct Pharma AB Transcript: CMD 2024
A refocused strategy prioritizes the ADVANCE phase II study in newly diagnosed, high-activity RA patients, aiming for data by end of next year and subsequent partnering. Resomelagon offers a novel, immune-preserving approach with strong efficacy in the right subgroup, addressing a large unmet need in RA and attracting significant industry interest.